Table 8

Recommended dosing for NOACs in the treatment of PE

Pharmacological agentRecommended dosing
ApixabanFirst 7 days–10 mg twice daily
After 7 days, reduce to 5 mg twice daily
≥6 months following treatment for PE, reduce to 2.5 mg twice daily (risk reduction for recurrent PE) 
No dose adjustment needed for PE treatment in renal failure patients (including patients on dialysis)
Dabigatran150 mg twice daily as a continuation treatment following initial course of parenteral anticoagulant for 5–10 days (CrCl >30 mL·min−1)
Dosing cannot be recommended for patients CrCl <30 mL·min−1 or on dialysis
Edoxaban60 mg once daily as a continuation treatment following initial course of heparin for at least 5 days
30 mg once daily (dose adjustment) needed for patients with CrCl 15–50 mL·min−1, body weight≤60kg, concomitant use of Pg-p inhibitors (e.g. dronedarone, cyclosporine, ketoconazole, erythromycin)
Rivaroxaban15 mg twice daily for the first 21 days and starting at day 22 change to 20 mg once daily (for patients with CrCl ≥15 mL·min−1)
10 mg once daily after ≥6 months of standard anticoagulant treatment (risk reduction for recurrent PE) in patients with a CrCl ≥15 mL·min−1
Avoid using rivaroxaban in patients with creatinine clearance <15 mL·min−1

Information from [6].